Beam Therapeutics BEAM Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$94.32M— | —— | -$112.73M-9.2% | -$103.23M+4.7% | -$108.33M-19.9% | ||
| $5.61M-1.1% | $5.67M+1.9% | $5.56M+0.4% | $5.54M+0.2% | $5.53M+1.6% | ||
| $19.04M-6.9% | $20.45M-10.1% | $22.75M-6.6% | $24.37M-8.7% | $26.68M-11.7% | ||
| $2.22M+85.6% | $1.19M— | —— | $2.64M-30.3% | $3.79M— | ||
| -$16.26M-214% | $14.3M— | —— | —— | -$18.46M-353% | ||
| $31.86M+54,102% | -$59K+96.4% | -$1.63M+41.5% | -$2.78M-5,569% | -$49K-101% | ||
| $134K+247% | -$91K+2.2% | -$93K-63.2% | -$57K+36.0% | -$89K-505% | ||
| -$6.36M+94.4% | -$113.82M-1,911% | -$5.66M+33.1% | -$8.47M-13.3% | -$7.47M-47.4% | ||
| $16K— | —— | $4.94M+11.8% | $4.42M+312% | -$2.08M-90.9% | ||
| —— | —— | —— | —— | —— | ||
| -$3.49M+0.2% | -$3.5M-3.5% | -$3.38M-1.7% | -$3.33M-0.8% | -$3.3M-0.7% | ||
| $35K— | —— | —— | —— | $0— | ||
| -$514K— | —— | -$1M-3,671% | $28K+3.7% | $27K— | ||
| -$128.51M-54.3% | -$83.29M-2.2% | -$81.48M-6.6% | -$76.45M+26.4% | -$103.88M-36.0% | ||
| $2.23M-40.2% | $3.73M-25.5% | $5.01M+59.8% | $3.14M+2.3% | $3.07M+3.2% | ||
| $153.79M-57.4% | $361.04M+106% | $175.64M-47.4% | $333.94M-1.5% | $339.17M— | ||
| $181.29M— | —— | —— | $166.67M-23.2% | $217.15M— | ||
| —— | $63.79M0.0% | $63.79M0.0% | $63.79M0.0% | $63.79M— | ||
| $25.27M— | —— | —— | -$170.41M-36.2% | -$125.09M-199% | ||
| $93.89M— | —— | —— | —— | $0— | ||
| $2.03M+7.4% | $1.89M+358% | $412K-76.5% | $1.76M+144% | $719K-79.1% | ||
| $813K— | —— | —— | —— | $0— | ||
| $96.61M+5,022% | $1.89M+12.6% | $1.68M+51.0% | $1.11M-99.8% | $473.38M+13,645% | ||
| -$6.64M-125% | $27M+291% | -$14.15M+94.2% | -$245.75M-201% | $244.41M— | ||
| —— | $0— | $0— | $0— | $0— | ||
| $35K— | —— | —— | —— | $0— | ||
| -$514K— | —— | -$1M-3,671% | $28K+3.7% | $27K— | ||
| $2.53M+0.6% | $2.52M-2.1% | $2.57M-2.8% | $2.65M0.0% | $2.65M+7.0% | ||
| $2.5M+4,900% | $50K+102% | -$2.76M-340% | $1.15M-64.2% | $3.2M— | ||
| —— | $63.79M0.0% | $63.79M0.0% | $63.79M0.0% | $63.79M— | ||
| $16K— | —— | $4.94M+11.8% | $4.42M+312% | -$2.08M-90.9% | ||
| -$16.26M-214% | $14.3M— | —— | —— | -$18.46M-353% | ||
| -$3.49M+0.2% | -$3.5M-3.5% | -$3.38M-1.7% | -$3.33M-0.8% | -$3.3M-0.7% | ||
| $134K+247% | -$91K+2.2% | -$93K-63.2% | -$57K+36.0% | -$89K-505% | ||
| $31.86M+54,102% | -$59K+96.4% | -$1.63M+41.5% | -$2.78M-5,569% | -$49K-101% | ||
| $2.76M-15.2% | $3.26M-23.0% | $4.23M-8.3% | $4.62M+20.0% | $3.85M-17.0% | ||
| $181.29M-16.9% | $218.03M-9.4% | $240.64M+44.4% | $166.67M-23.2% | $217.15M+68.0% | ||
| —— | $63.79M0.0% | $63.79M0.0% | $63.79M0.0% | $63.79M— | ||
| $813K— | —— | —— | —— | $0— | ||
| —— | $0— | $0— | $0— | $0— | ||
| $1.51M— | —— | $1.26M— | —— | $1.5M— | ||
| $1.39M— | —— | $2.15M— | —— | $1.46M+280% | ||
| $0— | —— | —— | —— | $641K— | ||
| -$3.49M+0.2% | -$3.5M-3.5% | -$3.38M-1.7% | -$3.33M-0.8% | -$3.3M-0.7% | ||
| —— | $1.93M0.0% | $1.93M0.0% | $1.93M0.0% | $1.93M— | ||
| -$130.75M-50.2% | -$87.02M-0.6% | -$86.49M-8.7% | -$79.59M+25.6% | -$106.95M-34.8% | ||
| -$130.75M-50.2% | -$87.02M-0.6% | -$86.49M-8.7% | -$79.59M+25.6% | -$106.95M-34.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Beam Therapeutics's cash flow data come from?
- Every line is extracted from Beam Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.